Short answer
Biogen (BIIB) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026.
Biogen Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue and YoY change not provided in supplied MD&A excerpt
- Profitability and margin percentages not provided in supplied MD&A excerpt
- Apellis acquisition added SYFOVRE and EMPAVELI on May 14, 2026
- Solothurn facility operational and approved for LEQEMBI and TYSABRI manufacturing
- Headwinds from originator therapies, generics, biosimilars, pricing pressure and reimbursement uncertainty
Risk Factors
- New regulatory risk: OBBBA, enacted July 2025, introduces Medicaid changes with uncertain material impact beginning in 2027 and 2028
- LEQEMBI commercialization risk: U.S. subcutaneous starting-dose approval remains pending, with delays potentially reducing anticipated benefits
- Integration risk: May 2026 Apellis acquisition requires effective integration and commercialization of EMPAVELI and SYFOVRE
- Market risk: Increasing generic, biosimilar and originator competition may reduce branded-product prices and sales volumes
- Pricing risk: IRA drug negotiations, Medicare Part D redesign and potential MFN policies could pressure sales, especially Medicare-reliant products
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biogen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.